Cefixime + OrnidazoleThird Party Manufacturing in India

Cefixime and Ornidazole work through two distinct and complementary mechanisms to cover both aerobic bacteria and anaerobic or protozoal pathogens in a single formulation. Cefixime, a third-generation cephalosporin, exerts its bactericidal effect by binding to penicillin-binding proteins located in the bacterial cell wall, specifically inhibiting the transpeptidase enzymes that catalyse the cross-linking of peptidoglycan strands. This disruption of cell wall synthesis leads to osmotic instability and bacterial cell death. Cefixime is particularly effective against aerobic Gram-negative organisms such as Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and Neisseria gonorrhoeae, as well as Gram-positive organisms like Streptococcus pyogenes and Streptococcus pneumoniae. Ornidazole belongs to the 5-nitroimidazole class and acts through a fundamentally different mechanism. It enters microbial cells by diffusion, where its nitro group is reduced by bacterial nitroreductase enzymes under anaerobic conditions to form toxic intermediate compounds and free radicals. These reactive species damage microbial DNA by causing strand breakage, helix destabilisation, and inhibition of nucleic acid synthesis, ultimately leading to cell death. Ornidazole is active against anaerobic bacteria such as Bacteroides fragilis, Clostridium species, and Fusobacterium, as well as protozoal parasites including Entamoeba histolytica, Giardia intestinalis, and Trichomonas vaginalis. It has a longer half-life of 12 to 14 hours compared to other nitroimidazoles, allowing once or twice daily dosing.

Therapeutic Uses

Cefixime plus Ornidazole is indicated for mixed aerobic-anaerobic infections and polymicrobial conditions:

• Intra-Abdominal Infections: Covers both aerobic enteric Gram-negative bacilli and anaerobic gut flora in peritonitis, intra-abdominal abscesses, and biliary tract infections.
• Pelvic Inflammatory Disease and Genitourinary Infections: Addresses the polymicrobial aetiology involving Neisseria gonorrhoeae, Chlamydia trachomatis, and anaerobic pathogens.
• Diarrhoeal Diseases and Amoebic Dysentery: Effective against both bacterial enteropathogens and Entamoeba histolytica, making it useful for mixed diarrhoeal presentations.
• Dental and Orofacial Infections: Provides coverage for mixed aerobic-anaerobic infections commonly encountered in dental abscesses and periodontal infections.
• Post-Surgical Prophylaxis: Used to prevent wound infections following abdominal, gynaecological, and colorectal surgeries where both aerobic and anaerobic contamination is expected.

Why Manufacturers Choose This Combination

Cefixime plus Ornidazole is one of the most widely prescribed fixed-dose combinations in the Indian market, ranking among the top-selling antibiotic combinations across both retail and institutional channels. The combination is stocked in nearly every PCD franchise portfolio due to its broad clinical utility across gastroenterology, gynecology, surgery, and dental medicine. Indian manufacturers produce the combination in tablet form at the 200mg plus 500mg strength, with consistent year-round demand. The API for both molecules is readily available from Indian manufacturers, ensuring supply chain stability and competitive pricing. This makes it one of the most sought-after combination products for third party manufacturing in India, with consistent demand from PCD franchise operators and export-oriented companies.